Single vial kit formulation of DOTATATE for preparation of 177Lu‐labeled therapeutic radiopharmaceutical at hospital radiopharmacy. (12th March 2015)

• Record Type: Journal Article
• Authors: Mukherjee, Archana; Lohar, Sharad; Dash, Ashutosh; Sarma, Haladhar Dev; Samuel, Grace; Korde, Aruna
• Is Part Of: Journal of labelled compounds & radiopharmaceuticals. Volume 58:Number 4(2015)
• Page Start: 166
• Page End: 172
• Publication Date: 2015-03-12
• Subjects: Tracers (Chemistry) -- Periodicals; Radiopharmaceuticals -- Periodicals; 615.8424
• DOI: 10.1002/jlcr.3267
• Languages: English
• ISSNs: 0362-4803

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The clinical applications of radiolabeled somatostatin analogue <sup>177</sup>Lu‐DOTA‐Tyr<sup>3</sup>‐Thr<sup>8</sup>‐Octreotide (<sup>177</sup>Lu‐DOTATATE) constitute a promising treatment option for patients with disseminated and inoperable neuroendocrine (NET) tumors. Formulation of <sup>177</sup>Lu‐DOTATATE in hospital radiopharmacy under aseptic conditions in a safe and reliable manner is a major constraint for its extensive use. The present work was intended to develop a kit for the safe preparation of the therapeutic radiopharmaceutical, viz. <sup>177</sup>Lu‐DOTATATE of high quality that can be easily adapted at conventional hospital radiopharmacies. Single vial kits of DOTATATE were formulated and evaluated for suitability for radiolabeling as well as stability on its storage. Patient dose of <sup>177</sup>Lu‐DOTATATE (7.4 GBq) could be successfully prepared using semi‐automated in‐house setup that assures safe handling and high yields of product of pharmaceutical purity suitable for clinical use. Fast clearance of activity via renal route was observed in preclinical biodistribution studies of <sup>177</sup>Lu‐DOTATATE carried out in normal Swiss mice. Deployment of in‐house produced <sup>177</sup>LuCl<sub>3</sub>, cold kits and easy adaptability of synthesis setup at hospital radiopharmacy for preparation is likely to expand applications of peptide receptor radionuclide therapy.</p> </abstract>